| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 06/06/2023 | Keros Therapeutics, Inc. | KROS | Grant | Stock Option (right to buy) | 10k | $48.79 | $487.9k | | 06/06/2023 |
| 11/29/2022 | Keros Therapeutics, Inc. | KROS | Exercise (in-the-money or at-the-money) | Call Options (obligation to sell) | 3.5k | $0.00 | $0.4 | See footnote | 11/29/2022 |
| 11/29/2022 | Keros Therapeutics, Inc. | KROS | Exercise (in-the-money or at-the-money) | Call Options (obligation to sell) | 1.7k | $0.00 | $0.2 | See footnote | 11/29/2022 |
| 11/29/2022 | Keros Therapeutics, Inc. | KROS | Exercise (in-the-money or at-the-money) | Call Options (obligation to sell) | 1.9k | $0.00 | $0.2 | See footnote | 11/29/2022 |
| 10/21/2022 | UroGen Pharma Ltd. | URGN | Exercise | Stock Option (right to buy) | 32.7k | $5.94 | $194.4k | By Pontifax (Israel) III Limited Partnership | 10/21/2022 |
| 10/21/2022 | UroGen Pharma Ltd. | URGN | Exercise | Stock Option (right to buy) | 15.3k | $5.94 | $90.7k | By Pontifax Cayman III Limited Partnership | 10/21/2022 |
| 10/21/2022 | UroGen Pharma Ltd. | URGN | Exercise | Stock Option (right to buy) | 32.7k | $5.94 | $194.4k | By Pontifax (Israel) III Limited Partnership | 10/21/2022 |
| 10/21/2022 | UroGen Pharma Ltd. | URGN | Exercise | Stock Option (right to buy) | 15.3k | $5.94 | $90.7k | By Pontifax Cayman III Limited Partnership | 10/21/2022 |
| 06/16/2022 | UroGen Pharma Ltd. | URGN | Exercise | Stock Option (right to buy) | 2.2k | $5.00 | $11.1k | By Pontifax (Israel) III Limited Partnership | 06/16/2022 |
| 06/15/2022 | Eloxx Pharmaceuticals, Inc. | ELOX | Grant | Stock Options (Right to Buy) | 20k | $0.26 | $5.2k | | 06/15/2022 |
| 06/08/2022 | UroGen Pharma Ltd. | URGN | Grant | Stock Option (right to buy) | 6.8k | $7.06 | $48.1k | by Pontifax (Israel) III Limited Partnership | 06/08/2022 |
| 06/08/2022 | UroGen Pharma Ltd. | URGN | Grant | Stock Option (right to buy) | 3.2k | $7.06 | $22.5k | By Pontifax Cayman III Limited Partnership | 06/08/2022 |
| 06/06/2022 | UroGen Pharma Ltd. | URGN | Exercise | Stock Option (right to buy) | 1k | $5.00 | $5.2k | By Pontifax Cayman III Limited Partnership | 06/06/2022 |
| 06/06/2022 | UroGen Pharma Ltd. | URGN | Exercise | Stock Option (right to buy) | 1k | $5.00 | $5.2k | By Pontifax Cayman III Limited Partnership | 06/06/2022 |
| 06/01/2022 | Keros Therapeutics, Inc. | KROS | Grant | Stock Options (right to buy) | 8.3k | $32.95 | $273.3k | | 06/01/2022 |
| 06/07/2021 | UroGen Pharma Ltd. | URGN | Grant | Stock Option (right to buy) | 6.8k | $17.89 | $122k | by Pontifax (Israel) III Limited Partnership | 03/25/2021 |
| 06/07/2021 | UroGen Pharma Ltd. | URGN | Grant | Stock Option (right to buy) | 3.2k | $17.89 | $56.9k | By Pontifax Cayman III Limited Partnership | 03/25/2021 |
| 06/01/2021 | Keros Therapeutics, Inc. | KROS | Grant | Stock Option (right to buy) | 8.3k | $51.48 | $426.9k | | 06/01/2021 |
| 05/19/2021 | Eloxx Pharmaceuticals, Inc. | ELOX | Grant | Stock Option (Right to Buy) | 20k | $1.48 | $29.6k | | 05/19/2021 |
| 05/13/2021 | Eloxx Pharmaceuticals, Inc. | ELOX | Purchase | Common Stock | 1.3M | $1.35 | $1.7M | By Pontifax Investment Fund | 05/13/2021 |
| 05/13/2021 | Eloxx Pharmaceuticals, Inc. | ELOX | Purchase | Common Stock | 2.6M | $1.35 | $3.6M | By Pontifax Investment Fund | 05/13/2021 |
| 05/13/2021 | Eloxx Pharmaceuticals, Inc. | ELOX | Purchase | Common Stock | 1.4M | $1.35 | $1.9M | By Pontifax Investment Fund | 05/13/2021 |
| 05/13/2021 | Eloxx Pharmaceuticals, Inc. | ELOX | Purchase | Common Stock | 592.6k | $1.35 | $800k | By Pontifax Investment Fund | 05/13/2021 |
| 03/25/2021 | UroGen Pharma Ltd. | URGN | Exercise | Stock Option (right to buy) | 2.2k | $5.00 | $11.1k | by Pontifax (Israel) III Limited Partnership | 03/25/2021 |
| 03/25/2021 | UroGen Pharma Ltd. | URGN | Exercise | Stock Option (right to buy) | 1k | $5.00 | $5.2k | By Pontifax Cayman III Limited Partnership | 03/25/2021 |
| 03/24/2021 | UroGen Pharma Ltd. | URGN | Exercise | Stock Option (right to buy) | 1k | $5.00 | $5.2k | By Pontifax Cayman III Limited Partnership | 03/24/2021 |
| 01/22/2021 | Prevail Therapeutics Inc. | PRVL | Other | Common Stock | 1.6M | $0.00 | $0 | See Footnote | 01/22/2021 |
| 01/22/2021 | Prevail Therapeutics Inc. | PRVL | Disposition | Stock Option (Right to Buy) | 17k | $16.98 | $288.7k | | 01/22/2021 |
| 11/17/2020 | Keros Therapeutics, Inc. | KROS | Purchase | Common Stock | 26.6k | $50.00 | $1.3M | See footnote | 11/17/2020 |
| 11/17/2020 | Keros Therapeutics, Inc. | KROS | Purchase | Common Stock | 13k | $50.00 | $648.3k | See footnote | 11/17/2020 |
| 11/17/2020 | Keros Therapeutics, Inc. | KROS | Purchase | Common Stock | 14.4k | $50.00 | $720k | See footnote | 11/17/2020 |
| 11/17/2020 | Keros Therapeutics, Inc. | KROS | Purchase | Common Stock | 6k | $50.00 | $300k | See footnote | 11/17/2020 |
| 06/17/2020 | Prevail Therapeutics Inc. | PRVL | Grant | Stock Option (Right to Buy) | 17k | $16.98 | $288.7k | | 06/17/2020 |
| 06/08/2020 | UroGen Pharma Ltd. | URGN | Grant | Stock Option (right to buy) | 10k | $28.24 | $282.4k | | 06/08/2020 |
| 05/20/2020 | Eloxx Pharmaceuticals, Inc. | ELOX | Grant | Stock Option (Right to Buy) | 20k | $3.39 | $67.8k | | 05/20/2020 |
|